Effect of hepatitis C virus infection on the circulating levels of interleukin (IL)-22, IL-32 and IL-34 in non-Hodgkin lymphoma patients | ||||
| SECI Oncology Journal | ||||
| Volume 10, Issue 4, October 2022, Page 219-224 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Epidemiological studies have demonstrated an increased risk of non-Hodgkin lymphoma (NHL) in patients suffering from chronic hepatitis C virus (HCV) infection. The increased inflammatory response is a key driver for tumor progression and hence, it may worsen the NHL status, when associated with hepatitis like that occurring in HCV patients. Aim of the work: This study aimed to assess the serum levels of interleukin (IL)-22, IL-32α and IL-34 as potential inflammatory mediators in the group of NHL lymphoma with or without HCV. Subjects and methods: A group of 25 NHL patients with HCV along with a group of 31 NHL patients without HCV were enrolled in the study. Serum levels of IL-22, IL-32α and IL-34 were assessed using ELISA assay. Results: Serum levels of IL-22, IL-32α and IL-34 were significantly (p<0.001) elevated in NHL patients with HCV, compared to NHL patients without HCV. Conclusion: HCV infection may be involved in the development and progression of NHL via increasing the circulating levels of IL-22, IL-32α and IL-34. | ||||
| Keywords | ||||
| NHL; HCV; Interleukin-22; Interleukin-32α; Interleukin-34 | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 68 |
||||
